Literature DB >> 24304056

Riociguat for pulmonary hypertension.

Hossein-Ardeschir Ghofrani, Gerald Simonneau, Lewis J Rubin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24304056     DOI： 10.1056/NEJMc1312903

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Pulmonary vascular morphology as an imaging biomarker in chronic thromboembolic pulmonary hypertension.

Authors:  F N Rahaghi; J C Ross; M Agarwal; G González; C E Come; A A Diaz; G Vegas-Sánchez-Ferrero; A Hunsaker; R San José Estépar; A B Waxman; G R Washko
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 2.  Management of pulmonary hypertension and right heart failure in the intensive care unit.

Authors:  Jonathan Grinstein; Mardi Gomberg-Maitland
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

Review 3.  Role of sGC-dependent NO signalling and myocardial infarction risk.

Authors:  Jana Wobst; Thorsten Kessler; Tan An Dang; Jeanette Erdmann; Heribert Schunkert
Journal:  J Mol Med (Berl)       Date:  2015-03-04       Impact factor: 4.599

Review 4.  [Systemic sclerosis : What is currently available for treatment?]

Authors:  M O Becker
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

Review 5.  Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2014-11       Impact factor: 9.546

Review 6.  Riociguat: Something new in pulmonary hypertension therapeutics?

Authors:  Elangovan Shanmugam; Amrita Jena; Melvin George
Journal:  J Pharmacol Pharmacother       Date:  2015 Jan-Mar

7.  The Ability of Nitric Oxide to Lower Intraocular Pressure Is Dependent on Guanylyl Cyclase.

Authors:  Stefan Muenster; Wolfgang S Lieb; Gregor Fabry; Kaitlin N Allen; Shivani S Kamat; Ann H Guy; Ana C Dordea; Leandro Teixeira; Robert E Tainsh; Binglan Yu; Wei Zhu; Nicole E Ashpole; Rajeev Malhotra; Peter Brouckaert; Donald B Bloch; Marielle Scherrer-Crosbie; W Daniel Stamer; Markus H Kuehn; Louis R Pasquale; Emmanuel S Buys
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-09-01       Impact factor: 4.799

Review 8.  Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis.

Authors:  Tommaso Gori
Journal:  Int J Mol Sci       Date:  2020-04-13       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.